Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation

Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen · 2026

Read Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation by Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13529884.txt.

Description

Lawrence Cheng Kiat Ng leads a 2026 report on brexucabtagene autoleucel, a CAR T-cell treatment for mantle cell lymphoma that has come back or stopped responding. The Singapore team describes five older patients treated during 2025 and sets their course beside earlier patients who received donor stem cell transplants.

Every treated patient responded, and most reached a complete response. Fever-like cytokine release occurred in most patients without severe cases, while one person had mild nerve-related side effects. Results compared well with the transplant group despite harder starting disease. The report presents early Asian real-world support for this cell therapy.

Catalog record

CREATORLawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26755
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13529884

Browse the full library · About the Tower of Babel